The Test Demands What the Sickest Can't Produce

Tuberculosis kills 1.25 million people per year — more than any other single infectious agent — yet an estimated 4 million cases go undiagnosed annually. The best available rapid molecular test (GeneXpert MTB/RIF) requires sputum samples, electricity, instrument maintenance, and trained operators, confining it to district-level facilities or higher. Children, people living with HIV, elderly patients, and those with non-productive cough cannot reliably produce sputum, and 20% of TB cases in prevalence surveys are completely asymptomatic. The WHO's 2024 updated TPP is the first to unify sputum and non-sputum approaches and define three test classes (point-of-care, near-PoC, low-complexity), but no test meeting these specifications yet exists.

TB is concentrated in low- and middle-income countries (98% of cases), with India, Indonesia, Philippines, China, and Pakistan accounting for over half of the global burden. The 4-million-case diagnostic gap means millions receive no treatment, continue transmitting, and face preventable death. The WHO TPP modeling shows that a less accurate test deployed at true point-of-care with non-sputum specimens can achieve comparable or better case detection than current GeneXpert because increased access compensates for reduced sensitivity — but no such test has been developed.

Sputum smear microscopy has been the backbone of TB diagnosis for over a century but misses 40-60% of cases, especially in HIV co-infection and childhood TB. GeneXpert (2010) dramatically improved sensitivity but remains infrastructure-dependent: each instrument costs $17,000+, cartridges ~$8 each, and the platform requires stable electricity. Urine lipoarabinomannan (LAM) tests offer a non-sputum alternative but Alere LAM has low sensitivity except in advanced HIV. FujiLAM (next-generation) shows improved, potentially HIV-neutral sensitivity but is not yet commercially available. Oral/tongue swabs with GeneXpert Ultra have shown 87-92% sensitivity in Guinea but require the same GeneXpert infrastructure. Digital chest X-ray with AI is emerging as a triage tool but cannot confirm TB. The fundamental gap remains: no instrument-free, non-sputum test exists that can confirm TB at the point of first clinical encounter.

The WHO TPP defines the target: a point-of-care test requiring no electricity, cold chain, or equipment, with >=98% specificity and sensitivity sufficient to outperform current care cascades when access gains are modeled. The most promising approaches combine non-sputum specimen types (oral swabs, urine, exhaled breath) with isothermal amplification or novel biomarker detection on lateral flow platforms. A student contribution could address the measurement science: systematic comparison of oral swab vs. urine LAM vs. combined approaches against culture-confirmed TB in a high-burden clinic setting.

A team could design and bench-test a prototype lateral flow assay combining FujiLAM-type urine detection with an oral swab molecular component, evaluating whether the two specimen types are sufficiently complementary (targeting different patient subgroups: HIV-associated vs. general TB). Alternatively, a team could build a portable, battery-free isothermal amplification device optimized for oral swab specimens and test it against GeneXpert in simulated field conditions. Relevant disciplines: biomedical engineering, microbiology, global health, diagnostics design.